|Bid||7.00 x 800|
|Ask||7.30 x 1400|
|Day's range||7.13 - 7.59|
|52-week range||5.05 - 19.60|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||N/A|
|Earnings date||16 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has entered into an agreement with EMC Pharma, LLC for the exclusive right to manage, market and distribute Sonoma’s HOCl-based prescription dermatology and eye care products in the United States for an initial term of five years, subject to extension. EMC Pharma will also have a non-exclusive agreement to manage, market and distribute certain Microcyn-based wound care products into government channels.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) on behalf of Sonoma stockholders. Our investigation concerns whether Sonoma has violated the federal securities laws and/or engaged in other unlawful business practices.
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.